ConKay Medical Systems is developing a unique, completely adjustable annular repair catheter intended to treat valvular regurgitation with an initial focus on the tricuspid valve. The device mimics open-heart annuloplasty without opening the chest by leaving a minimal implant around the valve annulus and is designed to avoid pacemaker leads. Company claims its independent arms, novel anchor concepts, and broad annulus-size range could expand therapy to a much larger portion of patients. There are more than 70 million people worldwide with tricuspid regurgitation and the company positions its technology to address limitations of current devices and trials. The $1.8M seed financing will support company growth and continued development of the one-size-fits-all system. ConKay anticipates a next financing round in Q2 2024 to support first-in-human testing.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2024